TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, is pleased to announce a non-brokered private placement of up to 3,500,000 units of the Company (the “Units”) at a price of $1.00 per Unit, for aggregate gross proceeds of up to$3,500,000 CDN (the “Offering”). Each Unit will ...